In addition to the previously reported antitumor activity in acute myeloid leukemia, LSD1 inhibitors have shown lineage‐specific activity in SCLC cell lines and patient‐derived xenograft models [5, 6, 13, 14, 15]. Here, KDM1A is linked to acute myeloid leukemia.